Φορτώνει......

Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (> 50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1–21 or days 1–7 and 15–21, repeated every 28 days (4 treatment regimens). Responses were seen i...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Leuk Res
Κύριοι συγγραφείς:	Erba, Harry P., Othus, Megan, Walter, Roland B., Kirschbaum, Mark H., Tallman, Martin S., Larson, Richard A., Slovak, Marilyn L., Kopecky, Kenneth J., Gundacker, Holly M., Appelbaum, Frederick R.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	2013
Θέματα:	Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4247790/ https://ncbi.nlm.nih.gov/pubmed/24411921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.12.001
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

Παρόμοια τεκμήρια